Summary Eighty-eight patients presenting with operable breast cancer of 4 cm or greater in diameter (T2, T3, NO, NI, MO) have received primary systemic therapy. Response was assessed following 12 weeks of systemic therapy by linear regression analysis of changes in tumour volume. Definitive locoregional surgery (mastectomy n = 82, wide local excision n = 6) was performed on completion of systemic therapy (3-6 months). Response was observed in 24 (39%) of the 61 patients who received endocrine therapy; all 24 had tumours with an oestrogen receptor (ER) concentraton of > 20 fmol mb' cytosol protein. Cytotoxic therapy was reserved for patients with tumours of ER concentration <20 fmol mg-' cytosol protein (n = 27) or when endocrine therapy had failed (n = 20). Response was observed in 34 patients (72%). The overall survival rate at 3 years was 86%, with 81% remaining free from local relapse. We propose that the treatment policy outlined in this paper should now be tested against orthodox management by controlled randomised trial.
It has now been established from statistical analyses of large controlled randomised trials that the long term survival of patients with operable breast cancer can be improved by systemic endocrine or cytotoxic therapy (Early Breast Cancer Trialists ' Collaborative Group 1988) . These trials however have not defined which therapy is most suitable for an individual patient. Given the morbidity of cytotoxic therapy (Glass et al., 1981) an unselective policy is not ideal. Furthermore the value of tumour oestrogen receptor status (ER) in selecting patients for adjuvant hormonal therapy remains controversial (Palshof et al., 1985; Rose et al., 1985; Fisher et al., 1986; Rutquist et al., 1987; Bianco et al., 1988; Scottish Breast Cancer Trials Committee 1987; Nolvadex Adjuvant Trial Organisation 1988) .
In 1985 we initiated a study in which local surgical treatment was delayed in patients with large, but still technically operable breast cancer until the response of the primary tumour to systemic therapy had been assessed (Forrest et al., 1986) . We now report our experience with primary endocrine and cytotoxic therapy in 88 such patients.
Patients and methods

Patient population
Patients were considered for entry into the study if they presented with an invasive breast carcinoma 4 cm or greater in diameter (T2, T3, NO, NI, MO). Patients with evidence of tumour fixation to skin or pectoral muscle, lymphoedema of the skin, detectable metastases on routine clinical and radiological investigations (including bone scan) or with a history of cardiac or mental instability were excluded from the study. All patients were Karnofsky grade 0.
During the 4 year period between April 1985 and April 1989, 136 patients with tumours measuring 4 cm or greater presented to the Breast Unit of Longmore Hospital, of whom 88 were included in this study. Sixteen patients failed to fulfil the selection requirements, in five cases an incisional biopsy had been performed to confirm the diagnosis and had removed a large amount of tissue, while in 13 patients the tumour was either multifocal, partly cystic, bilateral or difficult to measure reliably. Seven The oestrogen receptor concentration of the pretreatment biopsy was determined by the dextran-coated charcoal adsorption method (Hawkins et al., 1975 (Hawkins et al., , 1981 .
Systemic therapy
Of the 88 patients included within this study 41 received only endocrine therapy, 27 received only cytotoxic therapy while 20 received both forms of therapy. Systemic therapy was commenced within 10 days of the wedge biopsy.
Pilot study
The first 36 patients all received primary endocrine therapy (Anderson et al., 1989) . In premenopausal women ovarian function was ablated initially by surgical bilateral oophorectomy (n = 5) and subsequently by the lutenising-hormone releasing-hormone analogue goserelin (Zoladex ICI 118630, subcutaneous implantation 3.6 mg depot preparation at 28 day intervals following 4 ml lignocaine local anaesthetic, n = 7). Postmenopausal women received either tamoxifen (20 mg per day, n = 11) or the aromatase inhibitor aminoglutethimide (500 mg plus 40 mg hydrocortisone acetate, n = 10). Three postmenopausal patients received goserelin as their primary therapy. Cytotoxic therapy was reserved for those patients whose tumours had failed to respond to endocrine therapy. The chemotherapeutic regimen used was four cycles of CHOP, i.e. cyclophosphamide 1 gm2, adriamycin 50 mg m-2, vincristine 1.4 mg m2 to a maximum of 2 g, all by i.v. bolus and oral prednisolone 40 mg per day for 5 days. The regimen was administered every 21 days. If cytopenia (WBC < 3,000 ml-3 or platelet count of < 100,000 ml-3) was presented on day 21, therapy was delayed until the cytopenia resolved. A dose adjusted course was then given.
Selective policy
Following the demonstration that no patient with an ER concentration of < 20 femtomols mg cytosol protein-' showed significant regression while receiving endocrine therapy (Anderson et al., 1989) , and indeed two thirds progressed (Table III) Side-effects Side-effects of therapy were assessed at weekly clinical interview. The morbidity associated with cytotoxic therapy was reported using the WHO toxicity grading system (Miller et al., 1981) .
Definitive locoregional surgery On completion of systemic therapy (3-6 months) mastectomy with extensive skin removal and axillary node clearance was performed in 82 patients, of whom 55 had simultaneous reconstruction by latissimus dorsi myocutaneous flaps. In six patients with complete clinical response, wide local excision of the previous tumour site was preferred; this being followed by radiotherapy in five cases. The excised specimen was submitted to histological examination.
Patients who had shown a significant response to preoperative endocrine therapy were continued on endocrine therapy following definitive locoregional surgery. Premenopausal patients proceded to oophorectomy, postmenopausal patients received tamoxifen at a daily dose of 20 mg. Further cytotoxic therapy was not given to any patient after surgery.
Survival
The follow-up period has been expressed from the time of initiating systemic therapy to the date of analysis. The median period of follow-up was 24 months (range 4-55 months). Locoregional relapse has been defined as recurrence confined to the chest wall, breast or axilla. Supraclavicular lymph node recurrence has been classified as distant metastasis, in keeping with the staging classification for disease at initial presentation (International Union Against Cancer, 1987 TMN classification).
Results
Response to endocrine therapy Twenty-four of the 61 (39%) patients treated by initial endocrine therapy had significant regression of their tumours (Table III ). All responding tumours had an ER concentration of > 20 fmol mg cytosol protein-'. The proportion of patients achieving regression did not vary greatly in relation to the Figure 2 ). Those patients with steeper regression slopes were more likely to achieve complete clinical response within the time scale of the study.
There was no significant relationship between significant regression to chemotherapy and the pretreatment variables of age, menopausal status, initial clinical tumour size or pathological axillary node status (Table IV) . Of -those who failed to respond to endocrine therapy, chemotherapy was more likely to achieve regression in ER-poor tumours (Table  IV) . The overall, distant disease-free and disease-free survival of all patients within the study is shown in Figure 3 . Local recurrence-free survival is shown in Figure 4 Figure 3 Overall, distant disease-free and rela for 88 patients with large operable breast ca primary systemic therapy before definitive loco The median period of follow-up was 24 mon months). Elapsed time (months) Figure 4 Cumulative proportion remaining fre lapse in 88 patients with operable breast cancer< 4 cm at diagnosis treated with primary systemi definitive locoregional surgery. The median peri was 24 months (range 4-55 months).
apse-free survival ancer treated by regional surgery. ths (range 4-55 adverse effects included a tender lump at the injection site (n = 4), hot flushings (n = 2), erythematous rash on buttocks (n = 1), and a clinically insignificant, self-limiting abnormality of liver function tests (n = 2). Four patients who received aminoglutethimide complained of nausea and lethargy on initiation of therapy.
The chemotherapeutic regime was moderately toxic. The principle side-effects were alopecia (100%), nausea and vomiting (91% WHO grade 2 or greater), stomatitis (68% WHO grade 2), dyspepsia (20%) mild dysuria (13%) and neutropenia (26% WHO grade 2 or greater). Premature termination of therapy was required in two patients because of nonspecific toxicity and in one on account of iliofemoral thrombosis. There were no treatment related deaths and no increase in morbidity associated with definitive surgery. (Hawkins, 1985; Coombes, Stein & Dowsett, 1989; Nicholson & Waler, 1989 Within this study cytotoxic therapy with its greater associated toxicity was reserved for patients in whom endocrine therapy had failed or the likelihood of response to endocrine therapy was minimal (i.e. patients with ER-poor or ER-negative tumours). The proportion of such patients with tumours which were chemosensitive was high and lies within the observed range of 70-93% described with 'neoadjuvant' chemotherapy in more locally advanced breast cancers (Jacquillat et al., 1988; Hortobagyi et al., 1988; Swain et al., 1987) . Of those individual tumours directly demonstrated as endocrine-resistant however the proportion of ER-poor/ negative tumours regressing with chemotherapy paralleled that of primary chemotherapy (-80%) In addition to the benefit of selecting appropriate systemic therapy, there is theoretical (Goldie & Coldman, 1979; Skipper 1964) , experimental (Fisher et al., 1983) and clinical (Nissen-Meyer et al., 1986; Ragaz, 1986) 
